2 March 2023 - For the past six months, 14-year-old Freya Goldston has attended more school, swimming training and increased her time with friends — but that quality of life is now at risk.
Fiasp, the ultra-fast insulin she relies on to treat her type 1 diabetes will be taken off the Pharmaceutical Benefits Scheme (PBS) next month, sending the price soaring.